多替诺雷在高尿酸血症与痛风治疗中的研究进展

郑媛媛 ,  布玉露 ,  吴惠珍

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (10) : 1410 -1416.

PDF (471KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (10) : 1410 -1416. DOI: 10.12092/j.issn.1009-2501.2026.10.012
综述与讲座

多替诺雷在高尿酸血症与痛风治疗中的研究进展

作者信息 +

Research progress on dotinurad in the treatment of hyperuricemia and gout

Author information +
文章历史 +
PDF (481K)

摘要

高尿酸血症作为嘌呤代谢紊乱引发的代谢异常综合征,患病率呈显著上升趋势,已成为重要的公共卫生问题。目前常用降尿酸药物因安全性局限亟须新治疗选择。多替诺雷作为新一代选择性尿酸重吸收抑制剂,通过精准靶向肾近端小管顶膜尿酸转运体 1(URAT1)发挥治疗作用,其作用机制为选择性抑制 URAT1 介导的尿酸 Cl−/有机阴离子交换重吸收通路,促进尿酸排泄,有助于维持长效稳态血药浓度。其主要经葡萄糖醛酸化/硫酸化代谢,轻中度肝肾功能不全者无需调整剂量,年龄性别差异无临床意义,且药物相互作用风险低。本文对多替诺雷的作用机制、药理研究、临床有效性和安全性等进行综述,为高尿酸血症伴痛风的治疗提供更多思路和选择。

Abstract

Hyperuricemia, a metabolic disorder syndrome caused by dysregulation of purine metabolism, exhibits a significantly rising prevalence rate in China and has become a major public health concern. Currently available urate-lowering drugs face limitations in safety profiles, necessitating novel therapeutic options. Dotinurad, as a new-generation selective inhibitor of uric acid reabsorption, exerts its therapeutic effect by precisely targeting the urate transporter 1 (URAT1) on the apical membrane of renal proximal tubules. Its molecular mechanism involves the selective inhibition of the URAT1-mediated uric acid Cl-/organic anion exchange reabsorption pathway, thereby promoting uric acid excretion. This agent possesses pharmacokinetic characteristics including low volume of distribution and high plasma protein binding, ensuring long-lasting stable blood concentrations. It is primarily metabolized via glucuronidation/sulfation conjugation. Dosage adjustment is not required for patients with mild-to-moderate hepatic or renal impairment. Age and sex differences do not significantly affect its pharmacokinetics, and it carries a low risk of drug-drug interactions. This article reviews the fundamental profile, pharmacological research, clinical efficacy, and safety of dotinurad, aiming to provide expanded perspectives and alternatives for managing hyperuricemia with gout.

关键词

多替诺雷 / 选择性尿酸重吸收抑制剂 / URAT1 转运体 / 高尿酸血症 / 痛风

Key words

dotinurad / SURI / URAT1 / hyperuricemia / gout

引用本文

引用格式 ▾
郑媛媛,布玉露,吴惠珍. 多替诺雷在高尿酸血症与痛风治疗中的研究进展[J]. 中国临床药理学与治疗学, 2026, 31(10): 1410-1416 DOI:10.12092/j.issn.1009-2501.2026.10.012

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

中华医学会内分泌学分会. 中国高尿酸血症与痛风诊疗指南 (2019)[J].中华内分泌代谢杂志, 2020, 36(1): 1-13.

[2]

Dalbeth N, Gosling AL, Gaffo A, et al. Gout[J].Lancet, 2021, 397(10287): 1843-1855.

[3]

Zhang M, Zhu X, Wu J, et al. Prevalence of hyperuricemia among Chinese adults: findings from two nationally representative cross-sectional surveys in 2015-16 and 2018-19[J].Front Immunol, 2022, 12: 791983.

[4]

程伟刚, 李浩林, 杨娟娟, 等. 基于 TLR4/Myd88/NF-κB 信号通路探讨清热散浊饮治疗高尿酸血症合并痛风性关节炎的作用机制[J].中国临床药理学与治疗学, 2025, 30(4): 456-463.

[5]

Omura K, Miyata K, Kobashi S, et al. Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor[J].Drug Metab Pharmacokinet, 2020, 35(3): 313-320.

[6]

Xue X, Yuan X, Han L, et al. Effect of clinical typing on serum urate targets of benzbromarone in Chinese gout patients: a prospective cohort study[J].Front Med (Lausanne), 2022, 8: 806710.

[7]

Xu S, Liu X, Ming J, et al. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia[J].Int J Rheum Dis, 2015, 18(6): 669-678.

[8]

Huang X, Du H, Gu J, et al. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia[J].Int J Rheum Dis, 2014, 17(6): 679-686.

[9]

吴芃, 王亮, 李海涛, 等. 高尿酸血症模型的建立及降尿酸药物的研究进展[J].中国病理生理杂志, 2021, 37(7): 1283-1294.

[10]

Japanese Society of Gout and Nucleic Acid Metabolism. Guideline for the management of hyperuricemia and gout[M]. 3rd ed. Tokyo: Japanese Society of Gout and Nucleic Acid Metabolism,2019.

[11]

Taniguchi T, Ashizawa N, Matsumoto K, et al. Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor[J].J Pharmacol Exp Ther, 2019, 371(1): 162-170.

[12]

Nakatani H, Fushimi M, Sasaki T, et al. Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects[J].Clin Exp Nephrol, 2020, 24(Suppl 1): 8-16.

[13]

Hou Z, Ma A, Mao J, et al. Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout[J].Expert Opin Drug Metab Toxicol, 2023, 19(12): 895-909.

[14]

Yanai H, Adachi H, Hakoshima M, et al. A possible exquisite crosstalk of urate transporter 1 with other urate transporters for chronic kidney disease and cardiovascular disease induced by dotinurad[J].Cardiol Res, 2023, 14(2): 158-160.

[15]

Yanai H, Adachi H, Hakoshima M, et al. A possible therapeutic application of the selective inhibitor of urate transporter 1, dotinurad, for metabolic syndrome, chronic kidney disease, and cardiovascular disease[J].Cells, 2024, 13(5): 450.

[16]

Hosoya T, Sano T, Sasaki T, et al. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study[J].Clin Exp Nephrol, 2020, 24(Suppl 1): 44-52.

[17]

Hosoya T, Sano T, Sasaki T, et al. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study[J].Clin Exp Nephrol, 2020, 24(Suppl 1): 53-61.

[18]

Hosoya T, Fushimi M, Okui D, et al. Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout[J].Clin Exp Nephrol, 2020, 24(Suppl 1): 80-91.

[19]

Furihata K, Nagasawa K, Hagino A, et al. A drug-drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult males[J].Clin Exp Nephrol, 2020, 24(Suppl 1): 36-43.

[20]

Motoki K, Igarashi T, Omura K, et al. Pharmacokinetic/pharmacodynamic modeling and simulation of dotinurad, a novel uricosuric agent, in healthy volunteers[J].Pharmacol Res Perspect, 2019, 7(6): e00533.

[21]

Fukase H, Okui D, Sasaki T, et al. Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor[J].Clin Exp Nephrol, 2020, 24(Suppl 1): 17-24.

[22]

Kumagai Y, Sakaki M, Furihata K, et al. Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment[J].Clin Exp Nephrol, 2020, 24(Suppl 1): 25-35.

[23]

Omura K, Motoki K, Kobashi S, et al. Identification of human UDP-glucuronosyltransferase and sulfotransferase as responsible for the metabolism of dotinurad, a novel selective urate reabsorption inhibitor[J].Drug Metab Dispos, 2021, 49(11): 1016-1024.

[24]

Okui D, Sasaki T, Fushimi M, et al. The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor[J].Clin Exp Nephrol, 2020, 24(Suppl 1): 92-102.

[25]

McAdams-DeMarco MA, Maynard JW, Baer AN, et al. A urate gene-by-diuretic interaction and gout risk in participants with hypertension: results from the ARIC study[J].Ann Rheum Dis, 2013, 72(5): 701-706.

[26]

Takahashi T, Beppu T, Hidaka Y, et al. Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials[J].Clin Exp Hypertens, 2021, 43(8): 730-741.

[27]

Hosoya T, Sano T, Sasaki T, et al. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study[J].Clin Exp Nephrol, 2020, 24(Suppl 1): 62-70.

[28]

Hosoya T, Furuno K, Kanda S.A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout[J].Clin Exp Nephrol, 2020, 24(Suppl 1): 71-79.

[29]

朱楠, 侯杰, 李洁, 等. 降尿酸药物别嘌醇、非布司他和苯溴马隆的严重不良反应综述[J].中国合理用药探索, 2021, 18(6): 6-9.

[30]

曾大勇, 王长连, 黄品芳, 等. 福建汉族人群服用别嘌醇引起严重皮肤不良反应与 HLA-B*5801 关联性[J].中国医院药学杂志, 2015, 35(12): 1119-1121.

[31]

Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis[J].Arthritis Care Res, 2012, 64(10): 1447-1461.

[32]

Schumacher HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial[J].Arthritis Rheum, 2008, 59(11): 1540-1548.

[33]

White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout[J].N Engl J Med, 2018, 378(13): 1200-1210.

[34]

Yan F, Xue X, Lu J, et al. Superiority of low-dose benzbromarone to low-dose febuxostat in a prospective, randomized comparative effectiveness trial in gout patients with renal uric acid underexcretion[J].Arthritis Rheumatol, 2022, 74(12): 2015-2023.

[35]

Zhang MY, Niu JQ, Wen XY, et al. Liver failure associated with benzbromarone: A case report and review of the literature[J].World J Clin Cases, 2019, 7(13): 1717-1725.

[36]

Sun P, Zhu JJ, Wang T, et al. Benzbromarone aggravates hepatic steatosis in obese individuals[J].Biochim Biophys Acta Mol Basis Dis, 2018, 1864(6): 2067-2077.

[37]

Ishikawa T, Takahashi T, Taniguchi T, et al. Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout[J].Expert Opin Pharmacother, 2021, 22(11): 1397-1406.

基金资助

河北省卫健委、河北省红十字会 2026 年河北省医研企联合创新专项课题(LH20250020)

吴阶平医学基金会科研专项资助基金(320.6750.2025-18-14)

河北省医学适用技术跟踪项目(GZ2023035)

AI Summary AI Mindmap
PDF (471KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉